---
title: 'Life Sciences Daily Summary: What Happened on November 17, 2026'
headline: FDA rejects Summit’s ivonescimab application over survival data
description: Johnson & Johnson and Lilly agreed to multibillion-dollar acquisitions.
  Seawolf and Commit raised capital for drug programs.
url: https://thebench.bio/news/summaries/2026-11-17
topic: all
date: '2026-11-17'
covers:
- '2026-11-17'
date_published: '2026-11-17T12:04:56Z'
date_modified: '2026-11-17T12:04:56Z'
tags:
- Industry
- Regulatory
- Funding
sources: 12
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 17, 2026

**FDA rejects Summit’s ivonescimab application over survival data**

Johnson & Johnson and Lilly agreed to multibillion-dollar acquisitions. Seawolf and Commit raised capital for drug programs.

## Today in brief

Summit’s ivonescimab application for EGFR-mutated lung cancer did not clear the FDA’s bar for a statistically significant overall-survival benefit. [1] [2] Johnson & Johnson will pay $2.2 billion upfront for Ollin, while Lilly’s agreement to acquire Calytrix could reach $1.5 billion. [3] [4] Seawolf raised $100 million and entered a Sanofi partnership with potential payments of up to $1.2 billion. Commit raised $60 million for COM002. [5] [6]

## FDA rejects Summit’s ivonescimab application

The FDA rejected Summit Therapeutics’ application for ivonescimab with chemotherapy in locally advanced or metastatic non-small cell lung cancer after patients’ EGFR-mutated disease progressed on tyrosine kinase inhibitor treatment. [2] [7]

In the Phase 3 HARMONi trial, ivonescimab improved progression-free survival, but the primary overall-survival analysis did not reach statistical significance. [7] [8] Median overall survival was 16.8 months with ivonescimab and 14.0 months with chemotherapy alone, with a P value of .0570. [7]

The FDA said the progression-free survival result did not establish a favorable benefit-risk profile without a statistically significant overall-survival improvement. [2] [7] Summit said it would continue developing ivonescimab, which Akeso developed and which is authorized for certain uses in China. [2] [7]

## J&J pays $2.2 billion upfront for Ollin’s late-stage eye drug

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, with up to $1.125 billion more tied to regulatory and commercial milestones. [3] [9] Ollin’s lead candidate, OLN324, is a bispecific antibody in Phase 3 development for wet age-related macular degeneration and diabetic macular edema. [3] [10]

OLN324 targets VEGF and Ang2, pathways also targeted by Roche’s Vabysmo. [3] [10] Ollin reported that a Phase 1b comparison found numerically greater vision improvement and faster, greater structural changes with OLN324 than with Vabysmo. [10]

Johnson & Johnson will take responsibility for the pivotal trials. Blackstone Life Sciences will provide up to $750 million for late-stage development. [3] [10]

## Lilly agrees to acquire Calytrix for up to $1.5 billion

Eli Lilly agreed to acquire Calytrix Bio in a deal worth up to $1.5 billion, including an upfront payment and further payments tied to clinical and regulatory milestones. [4] [11] Calytrix is developing an antibody against Type 1 and Type 2 mutant calreticulin for essential thrombocythemia and myelofibrosis, blood cancers driven by abnormal blood-cell production. [4]

Calytrix says the antibody is designed to target mutant cells while sparing healthy tissue and normal blood-cell production. [4] Founded in 2025, Calytrix will have Lilly advance the program through clinical development, Lilly said. [4]

## Seawolf raises $100 million and signs Sanofi partnership

Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A financing and signed an exclusive research and licensing deal with Sanofi. [5] The deal covers treatments for bleeding disorders and other undisclosed conditions. Seawolf may earn research, development and commercial milestone payments, plus royalties. [5]

Seawolf’s TRIDENT platform uses lipid nanoparticles to deliver DNA that encodes a therapeutic protein into cell nuclei. [5] The company says the approach is intended to support longer-lasting protein production and allow repeat dosing. Seawolf has reported proof of concept in mice and nonhuman primates. [5]

## Commit Biologics raises $60 million for COM002

Commit Biologics raised a $60 million seed round led by Ackermans & van Haaren, with existing investors Novo Holdings, Bioqube Ventures and Korys participating. [6] AbbVie Ventures and M Ventures joined the company’s shareholder base in the financing. [6]

Commit plans to use the proceeds for regulatory filing preparations and other work before testing COM002 in people. [6] The company reported that COM002 depleted B cells in human whole-blood experiments and that one dose sustained depletion for more than four weeks in nonhuman primates. [6] These preclinical findings precede Commit’s plan to dose its first patient in early 2028. [6]

## Also worth knowing

- The FDA cleared Roche’s Wilserdly, bringing the company into the oral selective estrogen receptor degrader market. [12]
- The FDA approved Roche’s Gazyva to induce proteinuria remission in adults with primary membranous nephropathy at risk of progression. [8]
- The FDA approved AstraZeneca’s weekly self-injected Klygefa for adults with anti-AChR antibody-positive generalized myasthenia gravis. [8]

## The day in numbers

- **$2.2 billion**: Upfront payment in J&J’s agreement to acquire Ollin. [3]
- **$1.5 billion**: Maximum value of Lilly’s Calytrix acquisition, including milestone payments. [4]
- **$100 million**: Seawolf Therapeutics’ financing as it emerged from stealth. [5]
- **$60 million**: Commit Biologics’ seed round for COM002 development. [6]

## Sources

1. [FDA holds Summit to survival bar in ivonescimab CRL](<https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-17
2. [FDA rejects Summit’s ivonescimab application for lung cancer](<https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>), Pharmaceutical Technology, 2026-11-16
3. [J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences](<https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>), Pharmaceutical Technology, 2026-11-16
4. [Lilly agrees to acquire Calytrix Bio for $1.5bn](<https://www.pharmaceutical-technology.com/news/lilly-to-acquire-calytrix-bio-1-5bn/>), Pharmaceutical Technology, 2026-11-17
5. [Seawolf Therapeutics and Sanofi agree $1.2bn drug deal](<https://www.pharmaceutical-technology.com/news/seawolf-sanofi-agree-drug-deal/>), Pharmaceutical Technology, 2026-11-17
6. [Commit Biologics secures $60M to advance complement-based immunotherapies](<https://european-biotechnology.com/latest-news/commit-biologics-secures-60m-to-advance-complement-based-immunotherapies/>), European Biotechnology, 2026-11-17
7. [FDA Rejects Summit’s PD-1×VEGF Bispecific Ivonescimab in EGFR-Mutated NSCLC, Citing Lack of Survival Benefit](<https://www.biopharminternational.com/view/fda-rejects-summit-s-pd-1-vegf-bispecific-ivonescimab-in-egfr-mutated-nsclc-citing-lack-of-survival-benefit>), BioPharm International, 2026-11-16
8. [The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis](<https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis>), BioPharm International, 2026-11-16
9. [After gene therapy setbacks, J&J  pays $2.2B for Ollin, adds retinal disease candidate](<https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-16
10. [J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding](<https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>), MedCity News, 2026-11-16
11. [Pair of Lilly deals includes takeout of stealthy Calytrix for up to $1.5B: Deals Report](<https://www.biocentury.com/article/661629/pair-of-lilly-deals-includes-takeout-of-stealthy-calytrix-for-up-to-1-5b-deals-report?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-16
12. [Roche joins the oral SERD club as FDA clears Wilserdly](<https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly>), pharmaphorum, 2026-11-17

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>
[3]: <https://www.pharmaceutical-technology.com/news/jj-outlays-up-to-3-3bn-to-buy-ophthalmology-specialist-ollin-biosciences/>
[4]: <https://www.pharmaceutical-technology.com/news/lilly-to-acquire-calytrix-bio-1-5bn/>
[5]: <https://www.pharmaceutical-technology.com/news/seawolf-sanofi-agree-drug-deal/>
[6]: <https://european-biotechnology.com/latest-news/commit-biologics-secures-60m-to-advance-complement-based-immunotherapies/>
[7]: <https://www.biopharminternational.com/view/fda-rejects-summit-s-pd-1-vegf-bispecific-ivonescimab-in-egfr-mutated-nsclc-citing-lack-of-survival-benefit>
[8]: <https://www.biopharminternational.com/view/the-biopharm-brief-fda-rejects-ivonescimab-gazyva-becomes-the-first-approved-pmn-therapy-and-a-nanobody-approval-in-myasthenia-gravis>
[9]: <https://www.biocentury.com/article/661621/after-gene-therapy-setbacks-j-j-pays-2-2b-for-ollin-adds-retinal-disease-candidate?utm_source=bc_rss&utm_medium=rss>
[10]: <https://medcitynews.com/2026/11/johnson-johnson-jnj-ollin-biosciences-acquisition-bispecific-antibody-vegf-ang2-wet-amd-dme/>
[11]: <https://www.biocentury.com/article/661629/pair-of-lilly-deals-includes-takeout-of-stealthy-calytrix-for-up-to-1-5b-deals-report?utm_source=bc_rss&utm_medium=rss>
[12]: <https://pharmaphorum.com/news/roche-joins-oral-serd-club-fda-clears-wilserdly>
